The First Drug Built to Repair Mitochondria Directly

Mitochondrial dysfunction has been measurable in a research lab for decades — declining ATP output, rising oxidative stress markers — but for just as long, there's been no drug that intervened directly at the structural level. That changed in September 2025, when the FDA approved elamipretide, a peptide often referred to by its laboratory name, SS-31, described by researchers as the first therapy to directly target mitochondrial structure.

The mechanism centers on a single lipid: cardiolipin. Inside each mitochondrion, the inner membrane folds into tight pleats called cristae, and it's along those folds that the electron transport chain does the work of generating ATP. Cardiolipin is the structural lipid that holds the cristae folded correctly. When cardiolipin is damaged — a common consequence of oxidative stress that accumulates with age and in specific diseases — the folds collapse, and energy output drops along with it.

Elamipretide binds directly to cardiolipin and stabilizes its structure, allowing the folded architecture of the inner membrane to hold. It's a structural intervention, not a stimulant or a signaling molecule — it doesn't tell the cell to do anything differently, it just helps preserve the physical scaffolding energy production depends on.

The approval was earned through the TAZPOWER trial, conducted in patients with Barth syndrome, a rare genetic disorder involving cardiolipin abnormalities and severe energy deficits. Over 168 weeks, treated patients showed gains in muscle strength, reduced fatigue, and improved heart function.

It's worth being precise about scope: this approval covers one specific rare disease. Using elamipretide to address the ordinary, gradual mitochondrial decline associated with normal aging is not an approved use — it remains experimental and off-label, and hasn't been proven effective for that broader purpose. What the approval does establish is a genuine proof of concept: mitochondrial structural damage isn't necessarily permanent, and a drug can be built to specifically address it.

Why this matters for tracking: mitochondrial health shows up indirectly in things like resting energy expenditure, exercise recovery time, and certain metabolic bloodwork markers. As mitochondrial-targeted therapies mature beyond their initial rare-disease indications, having a personal baseline in these areas — tracked consistently rather than assessed once — is what will let you tell whether any future intervention is actually changing your own physiology.